Here are 1-3 brief analogies for SINTX Technologies:

• W.L. Gore & Associates for advanced silicon nitride materials.
• Corning, but focused on silicon nitride for biomedical and industrial solutions.

• Solid and Porous Silicon Nitride: Advanced ceramic materials used in medical devices, industrial applications, and for antipathogenic purposes.
• Silicon Nitride Powder: The foundational material in powdered form, used for manufacturing various silicon nitride products.
• Silicon Nitride Coating Products: Coatings applied to other materials to impart the beneficial properties of silicon nitride.
• Silicon Nitride Composite Materials: Engineered materials combining silicon nitride with other substances for enhanced performance.
• Polyetherketoneketone (PEKK): A high-performance polymer offered for advanced material applications.

SINTX Technologies (symbol: SINT) primarily sells its advanced materials and components to other companies, operating on a business-to-business (B2B) model, rather than directly to individuals.

While the company has indicated significant customer concentration in its financial filings (e.g., one customer often accounts for a substantial portion of its revenue), SINTX Technologies does not publicly disclose the specific names of its major customer companies in its SEC filings due to confidentiality agreements and competitive reasons. Therefore, it is not possible to list the names and symbols of these specific customer companies.

Based on the nature of SINTX Technologies' products and applications, its major customers would generally fall into the following categories:

• Medical Device Manufacturers: Companies that design, develop, and produce orthopedic, spinal, dental, and other medical implants and instruments, utilizing SINTX's silicon nitride for its biocompatibility, mechanical properties, and antibacterial characteristics.
• Industrial and Advanced Materials Companies: Businesses that integrate advanced silicon nitride materials into various industrial applications requiring high strength, wear resistance, or other specialized material properties.
• Companies in Antipathogenic Applications: Businesses developing products that leverage the unique antipathogenic properties of silicon nitride for surfaces, coatings, or components in healthcare, consumer, or industrial settings.

Eric K. Olson, President, Chief Executive Officer and Chairman of the Board

Mr. Olson has over 30 years of experience as a serial founder and entrepreneur in a range of medical device, diagnostic, biologic, and biomaterial companies. Most recently, he was the Founder, Chief Executive Officer, and Board Member of Foresite Innovations, LLC, a private healthcare innovation and development holding company. He previously served as CEO, President, and a Board Member of Amedica Corporation, the predecessor to SINTX, and played a key role in the company's 2014 initial public offering and listing on the NASDAQ Capital Market.

Kevin Trask, Chief Financial Officer

Mr. Trask joined SINTX in May 2025. Prior to SINTX, he was the Corporate Controller at USANA Health Sciences, Inc., a global, publicly traded company. Mr. Trask has held various management roles, leading and directing accounting and finance functions at several publicly traded companies. He began his career in public accounting, providing assurance services to both private and public companies.

Ryan Elmore, President

Mr. Elmore was appointed President, effective March 16, 2026. He brings over 15 years of experience in advanced biomaterials and medical device commercialization. Previously, he served as Core Business Director at Invibio, a division of Victrex plc. Mr. Elmore will lead efforts to expand the adoption of SiNERGY SiN/PEEK and advance silicon nitride technologies into new product categories.

Lisa Marie Del Re, Chief Commercial Officer

Ms. Del Re is a veteran executive with over fifteen years of experience in the medical device industry, focusing on commercialization, product strategy, and market expansion. She was the founder and CEO of a successful medical device distributorship. Ms. Del Re co-led M&A efforts at SiNAPTIC Surgical and held senior roles at companies such as Restor3d, Paragon 28 (acquired by Zimmer Biomet), TriMed (acquired by Henry Schein), and OsteoMed (acquired by Acumed-OsteoMed), where she helped drive growth.

Gregg R. Honigblum, Chief Investment Officer and Member of the Board

Mr. Honigblum has served as Chief Investment Officer since April 2025, and previously as Chief Strategy Officer from November 2024 to April 2025. He co-founded Creation Capital LLC and Creation Capital Advisors, investment banking firms that focused on founding and funding innovative healthcare technologies. Through Creation Capital, Mr. Honigblum provided over $100 million in private equity to Amedica (SINTX's predecessor) and has been an early financial backer.

The key risks to SINTX Technologies (SINT) are primarily centered around the challenging path to commercialization and sustained profitability for its silicon nitride technology in the medical device market, compounded by its ongoing need for additional financing.

1. Commercialization and Profitability Challenges: SINTX Technologies faces significant difficulties in fully commercializing its ceramic technologies and developing new product opportunities. Despite its advanced materials, the company is still in the early stages of generating substantial product sales, leading to expenses outpacing revenue and persistent unprofitability. The company needs to translate its innovations into sustainable profitability, which has not yet been achieved.
2. Need for Additional Financing and Weak Financial Health: The company is currently unprofitable, reporting negative net income and negative free cash flow, which indicates heavy investment without corresponding profit generation. SINTX will require additional financing to fund its product development programs and commercialization efforts. A failure to secure this funding could force the company to delay, reduce, or even eliminate these crucial initiatives. Its financial strength has been rated as poor.
3. Regulatory Hurdles and Market Adoption/Competition: As a medical device company, SINTX Technologies operates in a highly regulated environment, facing substantial challenges related to obtaining and maintaining regulatory approvals for its products. Additionally, the market for its applications, such as infection control, is competitive, and SINTX may struggle to capture significant market share against established players. The successful adoption of its silicon nitride products by healthcare providers and the broader market is not guaranteed.

SINTX Technologies operates in several key addressable markets related to advanced materials.

The global silicon nitride market, which encompasses its use in biomedical, industrial, and antipathogenic applications, including solid and porous silicon nitride, silicon nitride coatings, and composite materials, was valued at approximately USD 139.1 million in 2025 and is projected to grow to USD 265.1 million by 2034. The medical segment, where silicon nitride is used in devices, holds a significant share of this market.

For silicon nitride powder, a core product offered by SINTX Technologies, the global market size was valued at USD 98.5 million in 2023 and is projected to reach approximately USD 174.3 million by the end of 2032.

The global polyetherketoneketone (PEKK) market, another key material for SINTX Technologies, was valued at approximately USD 527.2 million in 2024 and is predicted to grow to around USD 1028.92 million by 2034.

SINTX Technologies (NASDAQ: SINT) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

1. Expansion into New Medical Device Markets and New Product Launches: SINTX Technologies is strategically focused on expanding its silicon nitride applications beyond spinal surgery into new medical markets, including orthopedic implants, dental products, and specifically, the foot and ankle market. A significant catalyst is the planned U.S. commercial launch of its FDA-cleared SiNAPTIC® Foot & Ankle Implant System in Q1 2026. The company is also developing next-generation hybrid biomaterials, combining silicon nitride with polymers like PEEK and PEKK for applications in spinal, oral/maxillofacial surgeries, and oncologic reconstruction.

2. Strategic Partnerships and Licensing Opportunities: The company is actively pursuing strategic partnerships and licensing opportunities to broaden the reach of its silicon nitride technology. This involves forming joint ventures with established manufacturers in sectors such as orthopedics, wound care, and agribiotech to integrate silicon nitride into new products. Additionally, SINTX aims to monetize its extensive patent portfolio through licensing agreements and technology transfer initiatives.

3. Growth in Antipathogenic Applications: SINTX is advancing its antipathogenic platform, particularly with new patent allowances for its antipathogenic fabric technology. This technology holds potential in the infection prevention market and for use in medical textiles like wound care, surgical masks, sutures, and drapes.

4. Commercialization of Advanced Silicon Nitride Composite Materials and 3D Printing: The company is enhancing its offerings through the development and commercialization of composite materials. This includes a supply agreement with EVONIK, signed in December 2025, to manufacture a silicon nitride-PEEK compound for AI-assisted, 3D-printed patient-specific implants. SINTX has also integrated silicon nitride into CFR-PEKK trauma plates, which is expected to deepen its penetration into the medical device industry.

5. Expansion into Agribiotech Applications: SINTX Technologies has identified agribiotech as an emerging field for its silicon nitride technology. A strategic shift in May 2025 included the expansion of intellectual property into these applications, indicating a new market focus for future revenue generation.

Capital Allocation Decisions (Last 3-5 Years)

Share Repurchases

• SINTX Technologies authorized a stock repurchase program in November 2024 to buy back up to $500,000 of its outstanding common stock over several quarters. This program represented approximately 20% of total outstanding shares at the time.

Share Issuance

• In February 2025, SINTX Technologies completed a $5.0 million private placement.
• As part of the SiNAPTIC Surgical acquisition in June 2025, SINTX issued $750,000 in common shares at $3.465 per share.
• The company expected to receive approximately $3.8 million in gross proceeds from the exercise of existing warrants in September 2025.

Inbound Investments

• SINTX Technologies underwent a recapitalization in February 2025.
• A $5.0 million private placement in February 2025 contributed to the company nearly doubling its cash on hand to $6.5 million by March 31, 2025.
• SINTX has raised a total of $122 million over 17 funding rounds.

Outbound Investments

• In June 2025, SINTX Technologies acquired the surgical business assets of SiNAPTIC Holdings, LLC to expand into the foot and ankle fusion market.
• SINTX sold its Maryland-based subsidiary, Technology Assessment & Transfer, Inc. (TA&T), in February 2025.
• In August 2024, the company officially shut down its armor ceramics facility, ceasing further investment in non-core technologies.

Capital Expenditures

• In 2021, SINTX purchased new equipment, including a 3D printer and a laser for texturing, for its research and development team to develop new composite products and advanced manufacturing processes for silicon nitride implants.
• The company received three NIH grants for developing 3D printed silicon nitride/polymer implantable medical devices.